CTLA4 and cholangiocarcinoma: Recent successes of immune checkpoint inhibitors, such as anti-PD-1/PD-L1 and anti-CTLA-4, in a variety of human malignancies, have led to increased research interest in the function of the immune microenvironment during cholangiocarcinoma development and progression [38,39,40,41].